Cancer cell line-derived exosomes is a powerful tool in the study of cancer research. Cancer cells release higher levels of exosomes compared to normal cells. These exosomes play a crucial role in cancer development and progression by facilitating the communication between cancer cells, other cells including immune cells and stromal cells, and their microenvironment. More specifically, exosomes released from cancer cells can promote cell proliferation, angiogenesis and invasion to contribute to tumor progression. Furthermore, they can facilitate metastasis by promoting the formation of metastatic niches, facilitating tumor cell escape from the primary tumor, and promoting the survival and growth of cancer cells in distant organs. In addition, they also contribute to drug resistance by delivering molecules that alter the drug-sensitive status of recipient cells. Last but not least, exosomes derived from tumor cells are able to modulate the immune system, suppress anti-tumor immunity and enable tumor cells to escape immune surveillance.
Meanwhile, clinical research indicated that cancer cells derived exosomes are potential biomarkers for cancer diagnosis and prognosis, and potential therapeutic targets with strategies aimed at inhibiting exosome release or delivery of specific exosomal molecules. Nowadays, exosomes are also engineered to deliver therapeutic drugs to enhance the effectiveness of cancer treatments.
AcceGen provides high-quality Cancer Cell Line-Derived Exosomes, enable researchers to investigate the complex communication within the tumor microenvironment, support studies on the molecular mechanisms of cancer development and progression, drug resistance, immune evasion and cancer diagnosis, and explore exosome-based therapeutic strategies for cancer treatment.
